Creation of an FDA approved analgesic ketamine drug with auto injector delivery system.
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH19C0193
- Awardee
-
Emergent Product Development Gaithersburg Inc. UEI CNPVCR8DK7M8
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $5,721,771
Award facts
- Opportunity
-
- Analgesic Ketamine Solicitation · W81XWH19R0032 · Posted May 21, 2019
- Contract value 100% obligated
- $5,721,770.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Montgomery Village, MD 20879, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$1,138,106 | |
| Supplemental Agreement for work within scope | -$4,200,843 | |
| Funding Only Action | -$6,787,812 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $6,787,812 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $4,396,498 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $1,000,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $5,664,222 |
Show all 14
About this award
This is a $5,721,770.90 definitive, cost-plus-fixed-fee contract awarded by the Defense Health Agency (DHA) to Emergent Product Development Gaithersburg Inc., a for-profit manufacturer of medical countermeasures and pharmaceuticals. The contract is for the creation of an FDA-approved analgesic ketamine drug with an auto-injector delivery system. The award is not associated with a larger contract vehicle and does not have a set-aside designation. The contract has a period of performance through February 29, 2024. Emergent has received over $1.3 billion in prime federal contracts from HHS and Defense agencies since 2019, including a $704 million contract to develop filovirus treatments and a $6.9 million DHA contract to develop this analgesic ketamine drug.
Quick answers
Who was awarded contract W81XWH19C0193?
W81XWH19C0193 was awarded to Emergent Product Development Gaithersburg Inc. by Medical Command (Department of the Army) on September 26, 2019.
How much is contract W81XWH19C0193 worth?
The government has obligated $5,721,771 on W81XWH19C0193.
Which agency awarded contract W81XWH19C0193?
Medical Command (Department of the Army) awarded W81XWH19C0193, with funding from Defense Health Agency (Department of Defense).
Was contract W81XWH19C0193 competed?
The extent of competition for W81XWH19C0193 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award